After surgery, a test detected cancer DNA before each observed colorectal recurrence; median lead: 4 months.
Myriad Genetics (MYGN) reported data from the MONSTAR-SCREEN-3 study, showing its Precise MRD™ platform detected cancer DNA before recurrence in colorectal and pancreatic cancer patients, with a median lead time of four months. The findings will be presented at the ESMO Congress 2026.
How this was made
The 30-second read
Why it matters
The disclosed data provide early evidence of clinical utility, which could accelerate product rollout and boost long‑term revenue forecasts.
Market read
First‑time release of promising MRD data may create buying interest in MYGN and related liquid‑biopsy stocks.
What to watch
Potential competition from other ctDNA platforms and the need for payer acceptance could temper market reaction.
Background
Myriad Genetics is a leading molecular diagnostic company; its Precise MRD platform uses whole‑genome sequencing to detect minimal residual disease in resectable cancers.
Ticker impact
Myriad Genetics disclosed new MONSTAR-SCREEN-3 data showing ultra‑sensitive MRD detection can identify colorectal cancer recurrence up to four months before clinical diagnosis.
potential upside as investors price in expanded market for MRD testing
First‑time disclosure of trial results; data are favorable and address a high‑need cancer monitoring segment.
Market effects
May lift other molecular diagnostics firms and increase investor focus on liquid biopsy technologies.
US biotech sector could see modest gains; European labs may see competitive pressure.
Supports broader trend of precision oncology and could influence global healthcare spending.
Counterpoint
If reimbursement or regulatory pathways stall, the data may not translate into revenue, limiting upside.
Key entities
- CompanyMyriad Genetics, Inc.
NASDAQ‑listed molecular diagnostics firm.
- Clinical StudyMONSTAR-SCREEN-3 study
Ongoing trial evaluating Precise MRD in colorectal and pancreatic cancers.
